Literature DB >> 24858734

Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma.

Ji Soo Choi1, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak.   

Abstract

Recently, higher body mass index (BMI) has been associated with aggressive pathologic features of papillary thyroid carcinoma. The aim of this study was to clarify the relationship between BMI and aggressive pathologic features of papillary thyroid microcarcinoma (PTMC) and to evaluate whether the BMI can be a prognostic factor of PTMC. This retrospective study included 612 PTMC patients who underwent surgical excision at a referral center between April 2006 and December 2007. Patients were grouped according to BMI (<25 or ≥25 kg/m2). Multivariable logistic regression analysis was performed to determine independent predictors of aggressive pathologic features (advanced stage, extrathyroidal extension, and lymph node metastasis), with adjustment for age, gender, tumor size, multifocality, thyroid stimulating hormone (TSH) level, and BMI (value/group). PTMC patients with a BMI≥25 kg/m2 showed significantly higher prevalences of extrathyroidal extension, advanced pathologic TNM stage, and male gender, compared to those of patients with a BMI<25 kg/m2. Lymph node metastasis and mean TSH level were not significantly different between the two BMI subgroups. In multivariable analysis, the BMI≥25 kg/m2 group was positively associated with the presence of extrathyroidal extension (adjusted odds ratio 1.49, P=0.05). Higher BMI was associated with extrathyroidal extension in PTMC patients. This study suggests that the BMI could be considered as a prognostic factor for predicting the presence of extrathyroidal extension and it may help decide the appropriate surgical extent for PTMC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24858734     DOI: 10.1007/s12020-014-0293-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

1.  Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies.

Authors:  Nicholas Mitsiades; Kalliopi Pazaitou-Panayiotou; Konstantinos N Aronis; Hyun-Seuk Moon; John P Chamberland; Xiaowen Liu; Kalliope N Diakopoulos; Vasileios Kyttaris; Vasiliki Panagiotou; Geetha Mylvaganam; Sofia Tseleni-Balafouta; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Should patients with papillary microcarcinoma undergo radioiodine ablation?

Authors:  Leonard Wartofsky
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

7.  Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study.

Authors:  Pauline Brindel; Françoise Doyon; Frédérique Rachédi; Jean-Louis Boissin; Joseph Sebbag; Larrys Shan; Vaiana Chungue; Frédérique Bost-Bezeaud; Patrice Petitdidier; John Paoaafaite; Joseph Teuri; Florent de Vathaire
Journal:  Cancer Causes Control       Date:  2008-11-30       Impact factor: 2.506

8.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

9.  Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching.

Authors:  Jandee Lee; Jae Hyun Park; Cho-Rok Lee; Woong Youn Chung; Cheong Soo Park
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

Review 10.  Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link.

Authors:  Stephen D Hursting; Laura M Lashinger; Karrie W Wheatley; Connie J Rogers; Lisa H Colbert; Nomeli P Nunez; Susan N Perkins
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-08       Impact factor: 4.690

View more
  18 in total

1.  Comment on: Lack of association between obesity and aggressiveness of differentiated thyroid cancer.

Authors:  A Campennì; F Trimarchi; S Baldari
Journal:  J Endocrinol Invest       Date:  2018-10-20       Impact factor: 4.256

Review 2.  The changing incidence of thyroid cancer.

Authors:  Cari M Kitahara; Julie A Sosa
Journal:  Nat Rev Endocrinol       Date:  2016-07-15       Impact factor: 43.330

3.  Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.

Authors:  Sunmi Park; Mark C Willingham; Jun Qi; Sheue-Yann Cheng
Journal:  Endocr Relat Cancer       Date:  2018-06-18       Impact factor: 5.678

Review 4.  Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models.

Authors:  Won Gu Kim; Sheue-Yann Cheng
Journal:  Horm Cancer       Date:  2018-01-19       Impact factor: 3.869

5.  Association between TNM staging system and histopathological features in patients with papillary thyroid carcinoma.

Authors:  Hye Jin Baek; Dong Wook Kim; Ji Hwa Ryu
Journal:  Endocrine       Date:  2014-07-23       Impact factor: 3.633

6.  Nodal metastasis and recurrence in papillary thyroid microcarcinoma.

Authors:  Adolfo Pisanu; Alessandra Saba; Mauro Podda; Isabella Reccia; Alessandro Uccheddu
Journal:  Endocrine       Date:  2014-07-10       Impact factor: 3.633

7.  Pretreatment BMI Is Associated with Aggressive Clinicopathological Features of Papillary Thyroid Carcinoma: A Multicenter Study.

Authors:  Shi-Tong Yu; Wanzhi Chen; Qian Cai; Faya Liang; Debin Xu; Ping Han; Jichun Yu; Xiaoming Huang
Journal:  Int J Endocrinol       Date:  2017-09-20       Impact factor: 3.257

8.  Does Obesity Cause Thyroid Cancer? A Mendelian Randomization Study.

Authors:  Jonathan Mark Fussey; Robin N Beaumont; Andrew R Wood; Bijay Vaidya; Joel Smith; Jessica Tyrrell
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

Review 9.  Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  R J O'Neill; S Abd Elwahab; M J Kerin; A J Lowery
Journal:  World J Surg       Date:  2021-06-16       Impact factor: 3.352

10.  Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis.

Authors:  Aliki Economides; Konstantinos Giannakou; Ioannis Mamais; Panayiotis A Economides; Panagiotis Papageorgis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-30       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.